SCHEMBL14224824

SCHEMBL14224824

CC(C)(C)OC(=O)N(CC(N)=O)CC(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.40
HDAC6 Q9UBN7 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
SSTR4 P31391 1/20 0.32
HDAC3 O15379 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
DGAT1 O75907 1/20 0.31
CTSD P07339 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11895925 0.92 CA14 (0.36) CA14HDAC6HDAC1HDAC2MAOA
SCHEMBL14030564 0.84 HDAC6 (0.42) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL20029121 0.84 CA14 (0.34) CA14HDAC6HDAC1HDAC2
SCHEMBL13315332 0.81 CA14 (0.33) CA14
SCHEMBL1926409 0.81 HDAC6 (0.36) CA14HDAC6HDAC1HDAC2MAOA
SCHEMBL28409176 0.80 CA14 (0.41) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL78691 0.80 CA14 (0.41) CA14HDAC6HDAC1HDAC2SSTR4
SCHEMBL8165566 0.80 ALOX5 (0.41) CA14CTSS
SCHEMBL13799225 0.78 CA14 (0.40) CA14HDAC6HDAC1HDAC2SSTR4
Glycine SCHEMBL28774225 0.78 GLRA1 (0.39) CA14HDAC6HDAC1HDAC2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293660-A1 CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF LA JOLLA PHARMACEUTICAL COMPANY (US) 2008-11-27 US disclosed
US-7351855-B2 Chemically defined non-polymeric valency platform molecules and conjugates thereof LA JOLLA PHARMACEUTICAL COMPANY (US) 2008-04-01 US disclosed
US-20070254851-A1 Chemically-defined non-polymeric valency platform molecules and conjugates thereof LA JOLLA PHARMACEUTICAL COMPANY 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293660-A1 CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF SSB, PCNA, NCL CA14 176/4885HDAC6 376/4885HDAC1 968/4885
US-20070254851-A1 Chemically-defined non-polymeric valency platform molecules and conjugates thereof SSB, PCNA, NCL CA14 176/4885HDAC6 376/4885HDAC1 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.